Oral solid dose formulations: Integrating patient centricity into development and lifecycle strategies
Oral solid dose (OSD) formulations continue to lead the market as a preferred drug form. The efficiency, cost effectiveness, shelf stability, and ease of administration of OSDs contribute to the appeal of the platform for enhancing existing formulations and transforming newer therapeutics such as peptides and biologics.
Importantly, because of their versatility, OSDs also play a key role in patient-centric drug design, which is critical for gaining advantage in today’s complex and competitive drug development landscape. The ability to alter and adjust such features as palatability and swallowability while optimizing dosing, bioavailability, release mechanism, and other performance attributes enables customization to meet the needs of specific patient populations.
The increasing demand for patient centricity in drug design together with the strong market for OSDs has led to the introduction of innovative technologies, materials, and processes to create products that have a direct impact on patient acceptability, such as taste-masked pediatric formulations, modified-release products, fixed-dose combination (FDC) products, multi-particulates, and orally dissolving tablets. Incorporating patient-specific considerations into drug product design can improve overall medication adherence, treatment compliance, and, ultimately, treatment outcomes.
The webinar will provide insight into the critical importance of patient centricity in OSD development, focusing on:
Thermo Fisher Scientific
Dr. Kane has more than 25 years of experience in the science and business of taking molecules through the entire drug development process. His extensive knowledge spans early stage development to scale-up and commercial manufacturing, and includes technical transfers between global sites and drug life cycle management. Dr. Kane received his Bachelors, Masters and Ph.D. degrees from the Bombay College of Pharmacy, University of Bombay, India, and served as a post-doctoral fellow at the School of Pharmacy, University of Cincinnati, Ohio. He has also earned an executive MBA from Richard Ivey School of Business, University of Western Ontario, Canada. Dr. Kane is a member of various international pharmaceutical professional organizations, and is often asked to speak about scientific topics on formulation, technology other technical aspects, QbD, etc at major industry events. He has also published many articles in International journals and delivered many talks at meetings and conferences cross the globe.
Date: Wednesday, December 1, 2021
Time: 11am ET / 8am PT
Duration: 1 Hour
Now Available On-Demand